Dendritic cell vaccines for melanoma: past, present and future

被引：13
作者：
Dillman, Robert O. [1 ,2 ,3 ]
Nistor, Gabriel I. [1 ,2 ,3 ]
Cornforth, Andrew N. [1 ,2 ,3 ]
机构：
[1] AiVita Biomed Inc, Clin Dept, 18301 Von Karman Ave,Suite 130, Irvine, CA 92612 USA
[2] AiVita Biomed Inc, Res Dept, 18301 Von Karman Ave,Suite 130, Irvine, CA 92612 USA
[3] AiVita Biomed Inc, Mfg Dept, 18301 Von Karman Ave,Suite 130, Irvine, CA 92612 USA
来源：
MELANOMA MANAGEMENT | 2016年 / 3卷 / 04期
关键词：
dendritic cells; immunotherapy; melanoma; patientspecific therapy; therapeutic vaccines; tumor-associated antigens;
D O I：
10.2217/mmt-2016-0014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Administering dendritic cells (DC) loaded with tumor-associated antigens (TAA) ex vivo is a promising strategy for therapeutic vaccines in advanced melanoma. To date the induction of immune responses to specific TAA has been more impressive than clinical benefit because of TAA limitations, suboptimal DC and possibly immune-checkpoint inhibition. Various products, antigen-loading techniques, treatment schedules, routes of administration and adjunctive agents continue to be explored. Biologic heterogeneity suggests autologous tumor as the optimal TAA source to induce immune responses to the entire repertoire of unique patient-specific neoantigens. Many questions remain regarding the optimal preparation of DC and strategies for antigen loading. Effective DC vaccines should result in additive or synergistic effects when combined with checkpoint inhibitors.
引用
收藏
页码：273 / 289
页数：17
相关论文
共 115 条
  • [1] Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells
    Aarntzen, Erik H. J. G.
    Srinivas, Mangala
    Bonetto, Fernando
    Cruz, Luis J.
    Verdijk, Pauline
    Schreibelt, Gerty
    van de Rakt, Mandy
    Lesterhuis, W. Joost
    van Riel, Maichel
    Punt, Cornelius J. A.
    Adema, Gosse J.
    Heerschap, Arend
    Figdor, Carl G.
    Oyen, Wim J.
    de Vries, I. Jolanda M.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (06) : 1525 - 1533
  • [2] Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell-Based Vaccination
    Aarntzen, Erik H. J. G.
    De Vries, I. Jolanda M.
    Lesterhuis, W. Joost
    Schuurhuis, Danita
    Jacobs, Joannes F. M.
    Bol, Kalijn
    Schreibelt, Gerty
    Mus, Roel
    De Wilt, Johannes H. W.
    Haanen, John B. A. G.
    Schadendorf, Dirk
    Croockewit, Alexandra
    Blokx, Willeke A. M.
    Van Rossum, Michelle M.
    Kwok, William W.
    Adema, Gosse J.
    Punt, Cornelis J. A.
    Figdor, Carl G.
    [J]. CANCER RESEARCH, 2013, 73 (01) : 19 - 29
  • [3] Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients
    Aarntzen, Erik H. J. G.
    Schreibelt, Gerty
    Bol, Kalijn
    Lesterhuis, W. Joost
    Croockewit, Alexandra J.
    de Wilt, Johannes H. W.
    van Rossum, Michelle M.
    Blokx, Willeke A. M.
    Jacobs, Joannes F. M.
    Duiveman-de Boer, Tjitske
    Schuurhuis, Danita H.
    Mus, Roel
    Thielemans, Kris
    de Vries, I. Jolanda M.
    Figdor, Carl G.
    Punt, Cornelis J. A.
    Adema, Gosse J.
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (19) : 5460 - 5470
  • [4] Final Version of 2009 AJCC Melanoma Staging and Classification
    Balch, Charles M.
    Gershenwald, Jeffrey E.
    Soong, Seng-jaw
    Thompson, John F.
    Atkins, Michael B.
    Byrd, David R.
    Buzaid, Antonio C.
    Cochran, Alistair J.
    Coit, Daniel G.
    Ding, Shouluan
    Eggermont, Alexander M.
    Flaherty, Keith T.
    Gimotty, Phyllis A.
    Kirkwood, John M.
    McMasters, Kelly M.
    Mihm, Martin C., Jr.
    Morton, Donald L.
    Ross, Merrick I.
    Sober, Arthur J.
    Sondak, Vernon K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6199 - 6206
  • [5] Banchereau J, 2001, CANCER RES, V61, P6451
  • [6] Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon
    Banchereau, J
    Ueno, H
    Dhodapkar, M
    Connolly, J
    Finholt, JP
    Klechevsky, E
    Blanck, JP
    Johnston, DA
    Palucka, AK
    Fay, J
    [J]. JOURNAL OF IMMUNOTHERAPY, 2005, 28 (05) : 505 - 516
  • [7] Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg
    Baur, Andreas S.
    Lutz, Manfred B.
    Schierer, Stephan
    Beltrame, Luca
    Theiner, Gabi
    Zinser, Elisabeth
    Ostalecki, Christian
    Heidkamp, Gordon
    Haendle, Ina
    Erdmann, Michael
    Wiesinger, Manuel
    Leisgang, Waltraud
    Gross, Stefanie
    Pommer, Ansgar J.
    Kaempgen, Eckhart
    Dudziak, Diana
    Steinkasserer, Alexander
    Cavalieri, Duccio
    Schuler-Thurner, Beatrice
    Schuler, Gerold
    [J]. BLOOD, 2013, 122 (13) : 2185 - 2194
  • [8] A tale of two pities Autologous melanoma vaccines on the brink
    Berd, David
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (08) : 1146 - 1151
  • [9] Boiko Alexander D, 2013, Methods Mol Biol, V961, P253, DOI 10.1007/978-1-62703-227-8_16
  • [10] Acquisition and Presentation of Tumor Antigens by Dendritic Cells
    Bonaccorsi, Irene
    Campana, Stefania
    Morandi, Barbara
    Ferlazzo, Guido
    [J]. CRITICAL REVIEWS IN IMMUNOLOGY, 2015, 35 (05) : 349 - 364
12345678910